Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Comparison between Ologen implant and different concentrations of MMC as an adjuvant to trabeculectomy

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Venue: Poster Village: Pod 2

First Author: : Z.Eldaly EGYPT

Co Author(s): :    A. Maasoud   M. Saad   A. Mohamed        

Abstract Details

Purpose:

To establish efficacy and safety of Ologen collagen implant versus different concentrations of Mitomycin C (MMC) in trabeculectomy.

Setting:

A prospective interventional open-label study was conducted in the Department of Ophthalmology, Assiut University, Egypt from May 2014 till August 2016.

Methods:

Patients with POAG, PNAG and secondary OAG were assigned equally either to Trabeculectomy augmented by Ologen implant, 0.4 mg/mL or 0.2 mg/mL MMC. Complete success was considered when IOP ≤ 15 mmHg, incomplete success when IOP ˃ 15 mmHg and ≥ 21 mmHg and failure when IOP ˃ 21 mmHg. Study outcome measures were reduction in intra-ocular pressure (IOP), success rates, survival analysis and rate of complications.

Results:

Thirty eyes were included. Baseline IOP in Ologen, MMC0.4 & MMC0.2 groups were 27.43 ± 2.97, 28.4 ± 3.24, 27.56 ± 2.69 mmHg respectively. At 6 months, mean IOP in Ologen, MMC0.4 and MMC0.2 groups were 18.55 ± 3.18, 16.2 ± 3.22, 16.93 ± 3.04 mmHg respectively. Complete success was achieved in 10%, 40% & 30% respectively in Ologen, MMC0.4 and MMC0.2. No treatment group difference reported by Kaplan- Meier analysis. Shallow AC occurred more in Ologen and MMC 0.4 groups, while hypotony occurred more in MMC0.4 and 0.2 groups. A single case of suprachoroidal effusion occurred in MMC0.4 group.

Conclusions:

Ologen implant may be a promising alternative to MMC for improving success rate of trabeculectomy. Though Ologen implant provided a safer surgical profile, MMC with different concentrations achieved a lower IOP reduction.

Financial Disclosure:

NONE

Back to previous